Today, GenMark Diagnostics announced it has entered into a heads of agreement with Advanced Liquid Logic (NYSE:ALL) defining the key terms of a collaboration between the two companies. GenMark and ALL will co-develop an all-electronic, fully integrated in-vitro diagnostic platform that unites ALL's proprietary electrowetting technology with GenMark's proprietary electrochemical detection.
The partnership will leverage the unique technologies and capabilities of both companies, delivering a digital sample-to-answer in-vitro diagnostic platform. The initial focus will be on multiplex molecular testing, followed by efforts in other diagnostics areas such as protein detection and point-of-care testing. The companies anticipate these efforts will redefine industry performance standards for even the most complex assays.
GenMark Diagnostics is an industry leader in providing automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets for the diagnosis of disease and the optimization of patient treatment. Utilizing the company's proprietary eSensor detection technology, GenMark's eSensor XT-8 system supports a wide range of molecular diagnostics tests with a compact, user-friendly workstation and self-contained, disposable test cartridges. GenMark currently markets three FDA-cleared tests for IVD use. A respiratory viral panel (NYSEMKT:RVP) has been submitted for 510(k) clearance by the FDA, and a number of other tests are presently in development for IVD use.
For more information, visit the company's Web site at genmarkdx.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net